Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the AKT Inhibitor GSK690693 Given on Various Schedules in Subjects With Solid Tumors or Lymphoma

NCT00493818 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00493818
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00493818 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the AKT Inhibitor GSK690693 Given on Various Schedules in Subjects With Solid Tumors or Lymphoma
Lead sponsor
GlaxoSmithKline
Phase
Phase 1
Overall status
Terminated
Start date
April 30, 2007
Completion date
June 30, 2008
Enrollment
70 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cancer